BioScale Announces First Installation of the ViBE™ Protein Analysis Workstation

First Customer Delivery to Further Oncology Biomarker Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BioScale Inc., an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, today announced the first shipment and installation of the ViBE™ Protein Analysis Workstation at a major Massachusetts-based pharmaceutical company. The ViBE Workstation will be used in support of oncology programs involving the discovery and validation of biomarkers associated with cancers.

“We at BioScale are pleased for the opportunity to support one of the world’s leading oncology-focused pharmaceutical companies in its biomarker research efforts,” said Mark Lundstrom, Chief Executive Officer at BioScale. “We expect the pace of research into complex diseases like cancer, diabetes, and Alzheimers will accelerate considerably as researchers uncover biomarkers that elucidate the diagnosis and improve treatment options. We believe the power and performance of the ViBE platform will allow pharmaceutical and biotech companies to cut drug discovery and development times and, one day, allow physicians to personalize treatments and provide more informative diagnostic tests.”

Chip Leveille, Chief Operating Officer at BioScale commented, “This shipment of the ViBE Workstation represents a major milestone for BioScale. It exemplifies the power of AMMP Technology and the ViBE Platform to those driving innovation in biomarker discovery and development. The simplicity and flexibility of the ViBE platform will provide scientists the ability to perform a wide range of protein analysis not only with more sensitive, reproducible data, but with the power to work in complex samples more quickly and efficiently than ever before.”

Powered by AMMP Technology, the ViBE platform enables advancements in protein research. AMMP (Acoustic Membrane MicroParticle) technology is a unique mechanical integration of magnetic microparticles, a universal sensor and acoustic science delivering a proprietary, non-optical protein detection and quantitation technique that is highly robust and versatile, with ease of methods transfer from traditional assay formats. The ViBE Workstation is the ideal tool for reliable, unattended sample analysis including reagent additions, incubation and real-time results with walkaway operation and is well suited for a variety of applications including biomarker discovery and development, bioprocess engineering and manufacturing.

ViBE Protein Analysis Workstations are now being shipped. For more information, contact [email protected], call 617-301-6100, or visit the company’s website at www.bioscale.com.

About BioScale

BioScale is a life science company that develops, manufactures and promotes a proprietary protein analysis technology to accelerate the discovery, development and production of biological and pharmaceutical products. BioScale’s innovative ViBE platform enables highly-sensitive detection and quantitation of proteins in complex samples used in pre-clinical and clinical research, bioprocess, patient point-of-care and personalized medicine applications. Founded in 2002, the Company is headquartered in Cambridge, MA. For more information, visit www.bioscale.com.

Forward Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding BioScale’s future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company's ability to obtain financing, the development and commercialization of ViBE systems, the prospects of the Company's protein analytics platform, the Company's strategies to develop and commercialize protein analytics systems and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. BioScale is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

BioScale logo, AMMP and ViBE are trademarks of BioScale, Inc.



CONTACT:

BioScale, Inc.
Investor Contact:
Caitlin Fenn, 617-301-6145
[email protected]
or
Media Contact:
Sharon Correia, 508-314-3155
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Genetics  Medical Devices  Oncology  Pharmaceutical  Other Health  Research  Other Science  Science

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.